D-Wave Quantum falls nearly 3% as earnings miss overshadows revenue beat
Investing.com -- Shares of Quantum (NASDAQ:QMCO) BioPharma Ltd. (NASDAQ: QNTM) surged 95% following the announcement of positive results from its clinical trial for the dietary supplement unbuzzd™. The trial confirmed that unbuzzd™ significantly accelerates the metabolism of alcohol, leading to a faster reduction in blood alcohol concentration (BAC) and alleviating symptoms of intoxication and hangover.
The Toronto-based biopharmaceutical company reported that the double-blind, randomized, placebo-controlled crossover design trial (NCT06505239) showed that unbuzzd™ dramatically reduced BAC in study subjects 40% faster on average within 30 minutes compared to a placebo. The findings also included statistically significant improvements in alertness and reductions in both perceived impairment and hangover symptoms, with no reported adverse side effects.
Dr. Andrzej Chruscinski, Vice President of Clinical and Scientific Affairs at Quantum BioPharma, expressed excitement over the "significant and meaningful outcomes" of the study. He highlighted the absence of product-related side effects and emphasized the supplement’s potential to mitigate the acute effects of alcohol intoxication.
Quantum BioPharma’s CEO, Zeeshan Saeed, remarked on the implications of unbuzzd™ for safer alcohol consumption, noting its ability to lessen intoxication, restore mental alertness, and help consumers avoid severe hangover symptoms.
unbuzzd™, developed by Quantum BioPharma’s team of scientists, is licensed to Celly Nutrition Corp. and available for purchase at https://unbuzzd.com. The company retains a 25.71% ownership stake in Celly Nutrition as of June 30, 2024, and is set to receive 7% of sales royalties until a total of $250 million is paid, after which the royalty rate will drop to 3% in perpetuity.
Quantum BioPharma is also involved in the development of treatments for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders, with its lead compound Lucid-MS designed to prevent and reverse myelin degradation associated with multiple sclerosis.
Today’s stock movement reflects investor enthusiasm for the potential market impact of unbuzzd™ and Quantum BioPharma’s broader portfolio of health solutions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.